Israeli company, MedCu has received approval from the Food and Drug Administration (FDA) to market a copper-based dressing product ideal for acute, diabetic and chronic wounds.
Following the approval, MedCu plans to raise $5 million at an estimated value of 20-25 million. MedCu Technologies is currently also seeking distributors in Europe and other territories.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Founded in 2016 by Danny Lustiger and Dr. Gadi Borkov, MedCu’s products are impregnated with materials that make up the bandages to create an antibacterial environment and prevent infections and healing difficulties. Copper is a natural mineral essential to the human body. It has been shown to be effective against a wide range of infections, including those that have developed resistance
Copper is environment-friendly. It has a long history of medicinal use based on its antimicrobial effect dating back to ancient times. The rationale for implementing copper is based on its ability to inhibit microbial growth and to support wound healing.
According to the company, the technology to combine oxidized copper with the polymeric is protected by over 30 patents, globally, and has been developed in over 15 years of intensive research.
The company explains that the wound dressing contains an internal absorbent layer and one or two external non-woven layers, all of which are impregnated with copper particles. Dressings are non-irritant, non-sensitizing.
